Regulatory Outlook finally claims FDA approval for AMD drug PharmaphorumAfter three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.OphthalmologyRead full story pharminent July 27, 2026 (Last updated: July 27, 2026) Pharmaphorum After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US. Ophthalmology Read full story Post navigation Previous: Outlook Therapeutics wins FDA approval for Lytenava in wet AMDNext: Argenx deepens immuno expertise with $2.2B Forte Biosciences buy Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026